Investor Relations

7 reasons to invest in Elanix

Elanix has the potential to disrupt the biotech industry, which is set to reach EUR 513 billion by 2020 (more info).

  • We develop and commercialise tissue regeneration products (learn more).
  • We are at the forefront of a revolution in applied regenerative medicine.

We have a diversified product portfolio with high growth potential across several important markets:

  • Advanced Wound Care (Medical Devices)
  • Advanced Skin Care
  • Cells as a Service

We apply a highly specialised Biotech approach to the medical device and cosmetics markets. This means:

  • Lower regulatory risk and lower entry cost.
  • Faster market entry and accelerated revenue generation.
  • Possibility to gradually increase sophistication of our products.

The Advanced Wound Care market was worth over USD 18 billion in 2017 (more info).

  • We have products in the pipeline for both Acute and Chronic Wound Care.
  • Our tissue regeneration tech improves and accelerates healing.
  • 10+ years of treating patients in acute and chronic wound care at the Lausanne University Hospital.

We have launched an advanced skin care product line on the European markets.

  • Targeted conditions affecting 300 million+ women worldwide.
  • Exclusive worldwide license for our proprietary CFPC® formulation.
  • Our first product GYNrepair (visit website) is already generating revenues.
  • Our next product SKINrepair will reach the market in 2018.

We license-out our cell technologies (Cells as a Service) to qualified partners and practitioners for specialised use.

  • Software – Wound Therapy Recommendation
  • Development of organoids
  • Clinical Services
  • R&D Services

Our progenitor cell bank is an ASSET with an audited value of EUR 24+ million.

  • Cell banks are GMP-certified (Good Manufacturing Practice)
  • Patented cell harvesting process in key economies (EU, USA, Japan, Taiwan, Hong Kong).
Investor Webcast 08 18

Elanix Flash Note Report by goetzpartners securities Limited (Aug. 2018)

Informational DOCUMENTS

Elanix Initiation Equity Research by goetzpartners securities Limited (Mar. 2018)